



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/719,007		
		Filing Date	November 20, 2003		
		First Named Inventor	JOHNSON, RANDOLPH MELLUS		
		Art Unit	1615		
Sheet	1	of	3	Examiner Name	Ghali, Isis A. D.
				Attorney Docket Number	DURE-007CON2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
IG		US-	3,998,834		12-21-1976	Janssen Pharmaceutica N.V.
IG		US-	5,202,128		04-13-1993	F.H. Faulding & Co. LTD
IG		US-	5,378,474		01-03-1995	F.H. Faulding & Co. LTD
IG		US-	5,910,301		06/08/1999	Farr, et al.
IG		US-	6,703,483		03-2004	Schiller, Peter
IG		US-	6,113,937		09-05-2000	Janssen Pharmaceutica N.V.
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
IG		WO 90/077333		07/12/1990	Purewal, et al.		
IG		WO 95/31182		11/1995	Farr, et al.		
IG		WO 92/02256		02/1992	Yaksh et al.		
IG		WO 2004/047839		06/10/2004	Chan, et al.		
IG		EP 0 267 617 A1		05/1988	Patel et al.		

Examiner Signature	/Isis Ghali/	Date Considered	08/24/2006
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	10/719,007	
			Filing Date	November 20, 2003	
			First Named Inventor	JOHNSON, RANDOLPH MELLUS	
			Art Unit	1615	
			Examiner Name	Ghali, Isis A. D.	
Sheet	2	of	3	Attorney Docket Number	DURE-007CON2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
IG		Fudin et al. "Use of Continuous Ambulatory Infusions of Concentrated Subcutaneous (SQ) hydromorphone versus intravenous (IV) Morphine: Cost Implications for Palliative Care" Am J Hospice Palliative Care 17:347-353 (2000).	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Ativan (2001) pp. 821.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Fentanyl (2001) pp. 826.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Meperidine (2001) pp. 828.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Morphine (2001) pp. 830.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Sulfentanil Citrate (2001) pp. 831-32.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Hydroxyzine Hydrochloride (2001) pp. 1193.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Duramorph (2001) pp. 1195-1197.	
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Duragesic (2001) pp. 1573-1577.	

Examiner Signature	/Isis Ghali/	Date Considered	08/24/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	10/719,007	
			Filing Date	November 20, 2003	
			First Named Inventor	JOHNSON, RANDOLPH MELLUS	
			Art Unit	1615	
Examiner Name	Ghali, Isis A. D.				
Sheet	3	of	3	Attorney Docket Number	DURE-007CON2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
IG		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Dilaudid (2001) pp. 1619-1623.	
IG		Ramsay, et al. "Immobilization of black bears (Ursus americanus) with orally administered carfentanil citrate", Database Biosis Online!, Biosciences Information Service, Philadelphia, PA US, database accession number PREV 100598404995, abstract (1995);	
IG		Ramsay, et al., "Immobilization of black bears (Ursus americanus) with orally administered carfentanil citrate", Journal of Wildlife Diseases, (1995), 31(3): 391-393	
IG		Scholz et al. "Clinical Pharmacokinetics of Alfentanil, Fentanyl and Sufentanil" Clin. Pharmacokinet. 31:275-92 (1996).	
IG		Stephens "Intrathecal Narcotics for Labor Analgesia" Am. Fam. Physician 56:463-70 (1997).	
IG		Vercauteren et al. "Postoperative Intrathecal Patient-Controlled Analgesia With Bupivacaine, Sufentanil or a mixture of Both" Anaesthesia 53:1022-7 (1998).	
IG		White "Clinical Uses of Intravenous Anesthetic and Analgesic Infusions" Anesth. Analg. 68:161-171 (1989).	
IG		Willens et al. "Pharmacodynamics, Pharmacokinetics, and Clinical Uses of Fentanyl, Sufentanil, and Alfentanil Heart Lung 22:239-52 (1993).	
IG		Roy and Flynn. "Solubility and Related Physicochemical Properties of Narcotic Analgesics", Pharm Research, 1988, vol. 5, no. 9, pgs 580-586.	

Examiner Signature	/Isis Ghali/	Date Considered	08/24/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.